September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
A real-world evaluation of frequency of ranibizumab and aflibercept deliveries for treatment-naïve patients with neovascular age-related macular degeneration: 12-month results from the French LYVE survey
Author Affiliations & Notes
  • Oudy Semoun
    Ophtalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
  • Rocio Blanco-Garavito
    Ophtalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
  • Salomon Y Cohen
    Centre Imagerie et Laser, Paris, France
  • Laetitia Finzi
    Retine, Novartis Pharma SAS, Rueil-Malmaison, France
  • Camille Maurin
    Retine, Novartis Pharma SAS, Rueil-Malmaison, France
  • Eric H Souied
    Ophtalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
  • Footnotes
    Commercial Relationships   Oudy Semoun, Bayer (C), Novartis (C); Rocio Blanco-Garavito, Novartis (C); Salomon Cohen, Alcon (C), Allergan (C), Bayer (C), Novartis (C), Thea (C); Laetitia Finzi, Novartis Pharma SAS (E); Camille Maurin, Novartis Pharma SAS (E); Eric Souied, Allergan (C), Bayer (C), Novartis (C), Thea (C)
  • Footnotes
    Support  Novartis Pharma SAS
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3340. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Oudy Semoun, Rocio Blanco-Garavito, Salomon Y Cohen, Laetitia Finzi, Camille Maurin, Eric H Souied; A real-world evaluation of frequency of ranibizumab and aflibercept deliveries for treatment-naïve patients with neovascular age-related macular degeneration: 12-month results from the French LYVE survey. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3340.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The LYVE survey employed a unique design that used two databases in France to evaluate the frequency of ranibizumab (RBZ) and aflibercept (AFL) deliveries over the 12-month follow-up period for treatment-naïve patients with neovascular age-related macular degeneration (nAMD) in routine medical practice.

Methods : LYVE was an observational, prospective, longitudinal survey analyzing 12-month data from two databases that recorded delivered products and patients’ information: a nationally representative pharmacy records database and a pharmacy-based questionnaire system. Treatment-naïve patients with nAMD who received their first RBZ/AFL prescription between October 2013 and July 2014 were enrolled (Figure 1). The primary objective was to evaluate the overall frequency of RBZ and AFL deliveries in a real-life setting in treatment-naïve patients with nAMD. Key secondary objectives were to evaluate the proportion of patients with a treatment switch (changed to a new treatment and maintained the same) or switch-back (changed from new treatment to the original treatment).

Results : Of the 2023 screened patients, 466 treatment-naïve patients (RBZ, n=314; AFL, n=152) were enrolled. Of the 400 patients with unilateral nAMD (RBZ, n=273; AFL, n=127), 220 treatment-naïve patients (RBZ, n=145; AFL, n=75) were analyzed during the 12-month follow-up. The baseline patient characteristics (age, gender) were well-balanced in both RBZ and AFL groups. The mean number of deliveries was 4.7, with no significant differences observed between the treatment groups (P=0.321; Figure 2). The mean time between RBZ and AFL deliveries was non-statistically different during the 12-month follow-up (P=0.357). No significant differences were observed between the two groups in terms of the proportion of patients who had a treatment switch (RBZ, n=31; AFL, n=8) or switch-back (RBZ, n=7; AFL, n=1).

Conclusions : LYVE represents a unique national sample of real-life data of nAMD treatment patterns in France. No statistically significant differences were observed between the treatment-naïve patients in terms of the frequency of RBZ and AFL deliveries over the 12-month follow-up period.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Data collection methodology-Constitution of a unique national sample

Data collection methodology-Constitution of a unique national sample

 

Time between ranibizumab and aflibercept deliveries

Time between ranibizumab and aflibercept deliveries

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×